BR112023020182A2 - Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula - Google Patents
Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célulaInfo
- Publication number
- BR112023020182A2 BR112023020182A2 BR112023020182A BR112023020182A BR112023020182A2 BR 112023020182 A2 BR112023020182 A2 BR 112023020182A2 BR 112023020182 A BR112023020182 A BR 112023020182A BR 112023020182 A BR112023020182 A BR 112023020182A BR 112023020182 A2 BR112023020182 A2 BR 112023020182A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- subject
- cell
- need
- treating cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 102000016914 ras Proteins Human genes 0.000 abstract 3
- 108010014186 ras Proteins Proteins 0.000 abstract 3
- 229940078123 Ras inhibitor Drugs 0.000 abstract 1
- -1 e.g. Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula. a divulgação apresenta métodos para inibir proteínas ras, por exemplo, proteínas ras que adquiriram resistência a um ou mais inibidores de ras. a divulgação também métodos para o tratamento de câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163170292P | 2021-04-02 | 2021-04-02 | |
US202163192843P | 2021-05-25 | 2021-05-25 | |
PCT/US2022/023133 WO2022212894A1 (en) | 2021-04-02 | 2022-04-01 | Methods for inhibiting ras |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023020182A2 true BR112023020182A2 (pt) | 2023-12-12 |
Family
ID=83456876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023020182A BR112023020182A2 (pt) | 2021-04-02 | 2022-04-01 | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240108630A1 (pt) |
EP (1) | EP4320143A1 (pt) |
JP (1) | JP2024512767A (pt) |
KR (1) | KR20240004436A (pt) |
AU (1) | AU2022249177A1 (pt) |
BR (1) | BR112023020182A2 (pt) |
CA (1) | CA3214155A1 (pt) |
CR (1) | CR20230500A (pt) |
IL (1) | IL307396A (pt) |
TW (1) | TW202308632A (pt) |
WO (1) | WO2022212894A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023199180A1 (en) * | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
WO2023232776A1 (en) * | 2022-06-01 | 2023-12-07 | F. Hoffmann-La Roche Ag | Haloindole macrocyclic compounds for the treatment of cancer |
CN117903169A (zh) * | 2022-09-19 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 一种pan-KRAS抑制剂化合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101602876B1 (ko) * | 2014-07-22 | 2016-03-11 | 아주대학교산학협력단 | 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용 |
-
2022
- 2022-04-01 WO PCT/US2022/023133 patent/WO2022212894A1/en active Application Filing
- 2022-04-01 CR CR20230500A patent/CR20230500A/es unknown
- 2022-04-01 TW TW111112802A patent/TW202308632A/zh unknown
- 2022-04-01 IL IL307396A patent/IL307396A/en unknown
- 2022-04-01 BR BR112023020182A patent/BR112023020182A2/pt unknown
- 2022-04-01 CA CA3214155A patent/CA3214155A1/en active Pending
- 2022-04-01 KR KR1020237037749A patent/KR20240004436A/ko unknown
- 2022-04-01 JP JP2023560831A patent/JP2024512767A/ja active Pending
- 2022-04-01 EP EP22782324.2A patent/EP4320143A1/en active Pending
- 2022-04-01 AU AU2022249177A patent/AU2022249177A1/en active Pending
-
2023
- 2023-10-02 US US18/479,500 patent/US20240108630A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20240004436A (ko) | 2024-01-11 |
CR20230500A (es) | 2024-02-13 |
TW202308632A (zh) | 2023-03-01 |
WO2022212894A1 (en) | 2022-10-06 |
US20240108630A1 (en) | 2024-04-04 |
IL307396A (en) | 2023-12-01 |
JP2024512767A (ja) | 2024-03-19 |
AU2022249177A1 (en) | 2023-10-19 |
EP4320143A1 (en) | 2024-02-14 |
CA3214155A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023020182A2 (pt) | Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula | |
CY1125065T1 (el) | Αναστολεις mcl-1 | |
BR112017020973A2 (pt) | método para tratar câncer em um paciente | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
EA201791258A1 (ru) | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени | |
GT201700246A (es) | Métodos y kits para tratar la depresión | |
BR112016029226A2 (pt) | métodos e composições para o tratamento de úlceras | |
BR112017010324A2 (pt) | método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula | |
BR112018012914A2 (pt) | composto, método para tratar, prevenir ou melhorar um ou mais sintomas de câncer, método para tratar, prevenir ou melhorar um ou mais sintomas de uma doença inflamatória e composição farmacêutica | |
BR112018074232A2 (pt) | compostos inibidores de egfr | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112015023207A2 (pt) | uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase | |
BR112019003172A2 (pt) | frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento | |
CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
BR112017012287A2 (pt) | uso de inibidores pan-fgfr e método de identificação de pacientes com câncer elegíveis para tratamento com um inibidor pan-fgfr | |
BR112018075135A2 (pt) | combinações farmacêuticas para tratar câncer | |
CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
CL2023000525A1 (es) | Inhibidores de sarm1 | |
BR112019011365A2 (pt) | métodos para tratar câncer | |
ECSP22053394A (es) | Inhibidores de sarm1 | |
BR112018005331A2 (pt) | inibidores de pcna | |
BR112018009528A2 (pt) | método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama | |
BR112019008241A2 (pt) | tratamento do prurigo nodular | |
BR112018014762A2 (pt) | método de tratamento da doença de alzheimer (da) precoce |